“biotech” Archives

in
Entry Author Date Location
HLI Adds Cynthia Collins as CEO, Venter Moves to Executive Chairman 01/04/17 San Diego
Digitalis Launches $100M Health Fund, With Emphasis On Data 01/04/17 New York
Versant Closes on $400M Fund, Eyes More Biotech Deals in Europe 01/03/17 San Francisco
First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work 01/03/17 Boston
Watching for NIH Innovation in 2017—and Drug Pricing, Trade Deals 01/02/17 San Diego
Varmus, Sato on Steering De Blasio’s $500M Plan to Grow NY Biotech 12/30/16 New York
Top of Texas 2016: Big Exits, Ride-Sharing Leaves Austin, & More 12/30/16 Texas
Gates Foundation Sends $140M to Intarcia for HIV Version of Pump 12/29/16 Boston
FDA Rejects Cempra Antibiotic, Asks for Another Clinical Trial 12/29/16 Raleigh Durham
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Anthera’s Shares Tumble After Cystic Fibrosis Drug Fails in Phase 3 12/28/16 San Francisco
Diabetes Study, Hiring News, Growth Mileposts, & More Local Tech News 12/27/16 Indiana
Liver Damage, Patient Deaths Lead FDA to Halt SeaGen Leukemia Trials 12/27/16 Seattle
East Coast Silicon Valley 12/27/16 Boston
Top Stories of 2016 for Xconomy Boston: Editor’s Picks 12/26/16 Boston
Ionis, Biogen Make History With FDA Nod for Spine Disease Drug 12/23/16 Boston
Texas Roundup: “1st & Future,” “Pink Tank” Pitch Contests, & More 12/23/16 Texas
Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More 12/23/16 National
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
Despite FDA Delay, Advocates Hopeful for New Genentech MS Drug 12/21/16 San Francisco
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) 12/21/16 National
Acadia Drug Shows Early Promise in Treating Alzheimer’s Psychosis 12/20/16 San Diego
CytoBiosciences Buys Alabama Company in ‘Multi-Million Dollar’ Deal 12/20/16 Texas
Biogen Promotes Vounatsos to CEO, Capping Scangos’s 6-Year Run 12/19/16 Boston
As Its Rivals Team Up, Editas Buys Next-Gen CRISPR From Old Friends 12/19/16 Boston
Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More 12/16/16 National
Flagship Pioneers New Name, $285M ‘Special Opportunities’ Fund 12/15/16 Boston
Goldfinch Bio Aims $55M and Cancer Strategy at Genetic Kidney Disease 12/14/16 Boston
Proteon’s Blood Vessel Drug Flunks Main Phase 3 Test, Shares Plummet 12/13/16 Boston
NY Bio Surge Continues as De Blasio Unveils $500M, 10-Year Life Sci Plan 12/13/16 New York
Page 2 of 244 « previous page · next page »